Health TrialsbyHealthPanel

Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)

ConditionsAcute StrokeIschemic Stroke
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNanjing First Hospital, Nanjing Medical University

About this trial

AISRNA is to analyze the expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with acute ischemic stroke and healthy control. The candidate circRNA/miRNA/lncRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Aged 18 years or older

Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan

Within 72 hours of symptom onset

Good performance status

Disqualifiers

None

Trial population

There will be 5 AIS patients and 5 HCs, whose data will be applied for construction of diagnostic and predictive models of circRNA/miRNA/lncRNA from the circulating blood. There will be 100 patients suspected of AIS (such as transient ischemic attack) 300 AIS patients, whose data will be applied for validation of such diagnosis and predictive models, respectively.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Sequencing of circRNA/miRNA/lncRNA

    Genetic

    Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)

Treatment groups

500 Participants
are divided into 2 treatment groups
Group A: AIS group1 intervention
Group B: HC group1 intervention

Trial outcomes

Primary outcomes

1

Differential expression pattern of circRNA/miRNA/lncRNA

Differential expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) will be compared between AIS group and HC group, thus candidate circRNA/miRNA/lncRNA will be verified as biomarkers for the detection and prognosis of AIS.

Time frame
90 days

Secondary outcomes

1

Prognostic value of circRNA/miRNA/lncRNA in acute ischemic stroke

The prognosis of AIS patients will be analyzed between differential expressed candidate miRNA/lncRNA after they have completed the systematic therapy.

Time frame
90 days
2

Correlation of circRNA/miRNA/lncRNA and inflammatory factors in acute ischemic stroke

Correlation of circRNA/miRNA/lncRNA and inflammatory factors on admission will be explored in acute ischemic stroke.

Time frame
7 days
3

Correlation of circRNA/miRNA/lncRNA and stroke-associated infection

Correlation of circRNA/miRNA/lncRNA and stroke-associated infection will be explored in acute ischemic stroke.

Time frame
30 days
4

Dynamic changes of circRNA/miRNA/lncRNA during the follow-up period

Dynamic changes of circRNA/miRNA/lncRNA will be explored before and after endovascular therapy

Time frame
90 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Nanjing First Hospital, Nanjing Medical University

Lead sponsor

Source ClinicalTrials.gov
Apply now